Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars

Teva said its “Pivot to Growth” strategy has entered phase two, supported by momentum in branded medicines, stabilization in its generics business, and an expanding biosimilars portfolio. Management also highlighted a strengthened balance sheet, signaling improved operating and financial positioning, though no new financial targets or performance figures were disclosed.